Provided by Tiger Trade Technology Pte. Ltd.

AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF

24.56
-0.1349-0.55%
Post-market: 24.55-0.0094-0.04%16:10 EDT
Volume:2K
Turnover:51.59K
Market Cap:5.65M
PE:- -
High:24.72
Open:24.72
Low:24.47
Close:24.69
52wk High:27.94
52wk Low:22.89
Shares:230.00K
Float Shares:230.00K
Volume Ratio:7.12
T/O Rate:0.91%
Dividend:0.41
Dividend Rate:1.68%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Is Hims & Hers Health (HIMS) A Bargain After The Fraud Lawsuit Claims?

Simply Wall St.
·
Yesterday

Viking Therapeutics Slides As Cash Raise Spooks Wall Street

TIPRANKS
·
Oct 03

Weight Loss Maintenance Data Could Be A Big Test For Viking Therapeutics Stock (VKTX)

Simply Wall St.
·
Oct 03

Is New Regional CMOs Altering The Investment Case For Hims & Hers Stock (HIMS)?

Simply Wall St.
·
Oct 03

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
Oct 03

Novo Nordisk Says FDA Review of Hemophilia Drug is Hitting Delays

Dow Jones
·
Oct 03

Hims & Hers Chief Legal Officer Soleil Boughton Disposes of 3,461 Common Shares Worth $100,964.37

Reuters
·
Oct 03

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
Oct 03

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Oct 03

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Oct 03

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Oct 03

Novo Nordisk Tests Zenagamtide Dosing to Sharpen Its Obesity Drug Pipeline

TIPRANKS
·
Oct 03

Novo Nordisk A/S Series B Stock Falls Friday, Underperforms Market

Dow Jones
·
Oct 03

Moderately bullish activity in Novo Nordisk with shares up 0.39%

TIPRANKS
·
Oct 02

Correction: Top Midday Decliners

MT Newswires Live
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Oct 02

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Oct 02

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01